189 related articles for article (PubMed ID: 29150104)
21. [Immunohistochemical prognostic factors of primary refractory Hodgkin's lymphoma].
Filatova LV; Gershanovich ML; Plotnikova AA; Turkevich EA; Ivantsov AO; Klimashevskiĭ VF
Vopr Onkol; 2014; 60(5):625-9. PubMed ID: 25816669
[TBL] [Abstract][Full Text] [Related]
22. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
23. Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma.
Gotti M; Nicola M; Lucioni M; Fiaccadori V; Ferretti V; Sciarra R; Costanza M; Bono E; Molo S; Maffi A; Croci GA; Varettoni M; Frigeni M; Pascutto C; Arcaini L; Bonfichi M; Paulli M; Cazzola M
Hematol Oncol; 2017 Sep; 35(3):296-302. PubMed ID: 27060262
[TBL] [Abstract][Full Text] [Related]
24. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
[TBL] [Abstract][Full Text] [Related]
25. Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
Bennett CL; Armitage JL; Armitage GO; Vose JM; Bierman PJ; Armitage JO; Anderson JR
J Clin Oncol; 1995 Apr; 13(4):969-73. PubMed ID: 7707125
[TBL] [Abstract][Full Text] [Related]
26. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.
Tzankov A; Meier C; Hirschmann P; Went P; Pileri SA; Dirnhofer S
Haematologica; 2008 Feb; 93(2):193-200. PubMed ID: 18223287
[TBL] [Abstract][Full Text] [Related]
27. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
28. [Clinical and Prognostic analysis of 43 Children with Mature B-cell Non-Hodgkin's Lymphoma/Acute Lymphoblastic Leukemia].
Guo J; Zhu YP; Gao J; Li Q; Jia CS; Zhou CY; Guo X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Feb; 24(1):72-9. PubMed ID: 26913397
[TBL] [Abstract][Full Text] [Related]
29. Peripheral blood lymphocyte/monocyte ratio at diagnosis and survival in classical Hodgkin's lymphoma.
Porrata LF; Ristow K; Colgan JP; Habermann TM; Witzig TE; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski GS; Thompson C; Markovic SN
Haematologica; 2012 Feb; 97(2):262-9. PubMed ID: 21993683
[TBL] [Abstract][Full Text] [Related]
30. Mitoxantrone, vinblastine, and lomustine (CCNU) (MVC): a highly active regimen for advanced and poor-prognosis Hodgkin's disease.
Wiernik PH; Dutcher JP; Einzig AI; Sparano J; Frank M; Friedenberg W
Cancer J Sci Am; 1998; 4(4):254-60. PubMed ID: 9689984
[TBL] [Abstract][Full Text] [Related]
31. Primary non-Hodgkin's lymphoma of bone in children.
Glotzbecker MP; Kersun LS; Choi JK; Wills BP; Schaffer AA; Dormans JP
J Bone Joint Surg Am; 2006 Mar; 88(3):583-94. PubMed ID: 16510826
[TBL] [Abstract][Full Text] [Related]
32. The expression of hepatitis B virus surface antigen in 120 Hodgkin's lymphoma patients.
Qiu MZ; Ruan DY; Wang ZQ; Luo HY; Teng KY; Xia ZJ; Lu Y; Huang HQ; Jiang WQ; Xu RH
Chin J Cancer; 2010 Aug; 29(8):735-40. PubMed ID: 20663320
[TBL] [Abstract][Full Text] [Related]
33. Non-Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group: incidence, treatment, and prognosis.
Rueffer U; Josting A; Franklin J; May M; Sieber M; Breuer K; Engert A; Diehl V;
J Clin Oncol; 2001 Apr; 19(7):2026-32. PubMed ID: 11310450
[TBL] [Abstract][Full Text] [Related]
34. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
[TBL] [Abstract][Full Text] [Related]
35. Outpatient-based ifosfamide, carboplatin and etoposide (ICE) chemotherapy in transplant-eligible patients with non-Hodgkin's lymphoma and Hodgkin's disease.
Hertzberg MS; Crombie C; Benson W; Taper J; Gottlieb D; Bradstock KF
Ann Oncol; 2003; 14 Suppl 1():i11-6. PubMed ID: 12736225
[TBL] [Abstract][Full Text] [Related]
36. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
[TBL] [Abstract][Full Text] [Related]
37. High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.
Lazarus HM; Crilley P; Ciobanu N; Creger RJ; Fox RM; Shina DC; Bulova SI; Gucalp R; Cooper BW; Topolsky D
J Clin Oncol; 1992 Nov; 10(11):1682-9. PubMed ID: 1403051
[TBL] [Abstract][Full Text] [Related]
38. Cancer-related fatigue in patients with and survivors of Hodgkin's lymphoma: a longitudinal study of the German Hodgkin Study Group.
Kreissl S; Mueller H; Goergen H; Mayer A; Brillant C; Behringer K; Halbsguth TV; Hitz F; Soekler M; Shonukan O; Rueffer JU; Flechtner HH; Fuchs M; Diehl V; Engert A; Borchmann P;
Lancet Oncol; 2016 Oct; 17(10):1453-1462. PubMed ID: 27612583
[TBL] [Abstract][Full Text] [Related]
39. Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma.
Dann EJ; Daugherty CK; Larson RA
Bone Marrow Transplant; 1997 Sep; 20(5):369-74. PubMed ID: 9339751
[TBL] [Abstract][Full Text] [Related]
40. Clinical Features and Prognostic Factors of Hodgkin's Lymphoma: A Single Center Experience.
Kılıçkap S; Barışta I; Ulger S; Celik I; Selek U; Yıldız F; Kars A; Ozışık Y; Tekuzman G
Balkan Med J; 2013 Jun; 30(2):178-85. PubMed ID: 25207097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
